Parallel Review Shouldn’t Entail Comparative Effectiveness, VCs Say

 
• By Cathy Kelly

Any parallel product review process developed by FDA and CMS should not involve new requirements for comparative effectiveness data, the Medical Innovation and Competitiveness Coalition urges in recent comments to the agencies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet